medigraphic.com
ISSN 1561-2945 (Print)

2011, Number 3

<< Back Next >>

Revista Cubana de Cirugía 2011; 50 (3)

Prognostic factors related to gastric cancer

Rodríguez FZ, Piña PL, Manzano HE, Cisneros DCM, Ramón FWL

Language: Spanish
References: 55
Page: 363-387
PDF size: 268.71 Kb.


ABSTRACT

The gastric cancer is the second more frequent malignant tumor prevailing in western countries but mainly in the Asiatic ones. The programs of early detection with imaging and oral endoscopy allowed to diagnose in initial stages and an increase in survival although the 60 % of patients are diagnosed in III or IV stages and global 5-years survival is from 5 to 15 %. The objective of present review was to identify the prognostic factors related to gastric cancer in dependence of the patient, of the own tumor and of the treatment, which may to affecting the appearance of the tumor relapse after surgery and to help to take into account appropriate therapeutics. In the biological variables of patient there is not a significant association with the prognosis of gastric cancer, unlike the grade of wall invasion, the ganglion involvement and the tumor biological factors. Surgery is the only potentially curative treatment, but it is not enough for many patients despite the wide lymphadenectomies. Around the 80 % of patients operated on will show relapse with a fatal prognosis. Chemotherapy, radiotherapy and immunotherapy have not changed yet in a significant way, the natural history of this disease. The postoperative follow-up can not be systematized due to the low sensitivity of methods to detect the relapse pattern, as well as the lack of its effectiveness treatment. The characterization of the prognostic factors of gastric cancer allows to stratify the patients and to select different treatments trying to increase the survival.


REFERENCES

  1. Ministerio de Salud. Guía Clínica Cáncer Gástrico. Serie Guías Clínicas MINSAL Nº 35. Santiago de Chile: MINSAL; 2006. p. 12-43.

  2. Parkin MD, Bray JF, Pisani F, Pisani P. Global Cancer Statistics 2002. Cancer J Clin. 2005;55:74-108.

  3. Yera Abreu L. Tumores del estómago. En: Enfermedades quirúrgicas del abdomen. Capítulo VIII. García Gutiérrez, Pardo Gómez. Cirugía Tomo III. La Habana: Editorial Ciencias Médicas; 2008. p. 1 160-74.

  4. Ministerio de Salud Pública. Dirección Nacional de Registros Médicos y Estadísticas de Salud. Anuario Estadístico de Salud. La Habana; 2009. p. 32-5, 40-9, 53.

  5. Jurado C. Cáncer gástrico: visión y misión de un cirujano endoscopista. Revisión de tema. Rev Colombiana Cir. 2008;21(2):85-99.

  6. Santoro E. The history of gastric cancer. Gastric cancer: legends and chronicles. Gastric Cancer Japan. 2005;8:71-4.

  7. Yan-Quiroz EF, Diaz-Plasencia JA, Burgos-Chávez OA, Rojas-Vergara M, Santillán-Medina J, Vilela-Guillén ES, et al. Factores pronósticos de sobrevida quinquenal de pacientes con carcinoma gástrico avanzado resecable con serosa expuesta. Rev Gastroenterol Perú. 2003;23:184-91.

  8. Sdteete G, Lynch O, Madariaga J, Zilic M, Martínez L, Schultz S, et al. Patrón pronóstico de invasión serosa (S2) en carcinoma gástrico. Rev Chilena de Cirugía. Diciembre 2002;54(6):644-8.

  9. Calpena R, Lacuela FJ, Oliver I, Cansado P, Pérez F, Costa D, et al. Estado actual del tratamiento multidisciplinario del cáncer gástrico avanzado. Cir Esp. 2003;74(2):69-76.

  10. Villafranca E, Arista J, Meiriño R, Dueña MT, Marcos M. Factores pronósticos del carcinoma gástrico. ANALES Sis San Navarra. 2001;24(Suplemento 1):111-20.

  11. Casariego E, Pita S, Rigueiro MT, Pértiga S, Rubañal R, García-Rodeja ME, et al. Supervivencia en 2334 pacientes con cáncer gástrico y factores que modifican el pronóstico. Medicina Clínica, Barcelona. 2001;117(10):361-5.

  12. Tahara E. Mechanisms of carcinogenesis: contributions of molecular epidemiology. Buffler PA, editor. Lyon: International Agency for Research on Cancer; 2004. p. 327-49.

  13. Rodríguez P. Carcinogénesis gástrica. En: Linhares E, Lourenco L, Sano T, editores. Actualización en cáncer gástrico. 2005;25:81-7.

  14. Batista Duharte A. Función del sistema inmune en la defensa contra tumores malignos. MEDISAN [serie en internet]. 2003 [citado 10 de octubre de 2010];7(2). Disponible en: http://bvs.sld.cu/revistas/san/vol7_2_03/san11203.htm

  15. Bormann R. Geschwuelste des Magens und Duodenum. En: Henke F, Lubarsch D, editors. Handbuch der Spezieller Pathologischen Anatomie und Histologie. Vol. 4. Berlin: Julius Springer; 1926. p. 128-35.

  16. Lauren P. The two histologic main types of gastric carcinoma: diffuse and socalled intestinal type carcinoma: an attempt at a histochemical classification. Acta Pathol Microbiol Scand. 1965;64:31-49.

  17. Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S. Pathology and prognosis of gastric carcinoma. Well versus poorly differentiated type. Cancer. 2000;89:1418-24.

  18. Chan A, Chun Yu, Wong Benjamín. Epidemiology of gastric cancer. [monografía en internet]. Walthman (MA): Update 2005 [citado 28 de octubre de 2008]. Disponible en: http://www.uptodate.com

  19. Aravena E. Helicobacter pylori y cáncer gástrico. Gastr Latinoam. 2007;18(2):129-32.

  20. Rubiano J, Velásquez M. Atrofia, metaplasia y cáncer gástrico, ¿dónde está la evidencia? Rev Colomb Cir. 2007;22:39-45.

  21. Hurtado M. Gastritis crónica atrófica, metaplasia intestinal, tratamiento. Rev Colomb Gastroenterol. 2007;22:4-6.

  22. Stomach. In: Edge SB, Fritz AG, Byrd DR, Greene FL, Trotti A, Compton CC editors. American Joint Committee on Cancer (AJCC). Cancer Staging Manual. 7th Edition. New York: Springer; 2010. p. 66-75.

  23. Casado Martín F, Domínguez Díaz A, Rodríguez Sanjuán JC, López Useros A, Cabrera García M, Moreno Muzas C, et al. Cirugía del cáncer gástrico precoz. Experiencia en 25 años. Gastroenterología y hepatología. 2001;24(9):123-35.

  24. Inoue K, Tobe T, Kan N. Problems in the definition and treatment of early gastric cancer. Br J Surg. 2001;78:818-21.

  25. Bruno M. Magnification endoscopy, high resolution endoscopy, and chromoscopy, towards a better optical diagnosis. Gut. 2003;52:7-11.

  26. Kiesslich R, Arjus M, Neurath F. Endomicroscopy. Gastrointest Endosc. 2007;66:153.

  27. Willis S, Truong S, Gribnitz S, Fass J, Schumpelick V. Endoscopic ultrasonography in the preoperative staging of gastric cancer: accuracy and impact on surgical therapy. Surg Endosc. 2000 Oct;14(10):951-4.

  28. Kelly S, Harris KM, Berry E, Hutton J, Roderick P, Cullingworth J, et al. A systematic review of the staging performance of endoscopic ultrasound in gastrooesophageal carcinoma. Gut. 2001 Oct;49(4):534-9.

  29. Kinkel K, Lu Y, Both M, Warren RS, Thoeni RF. Detection of hepatic metastases from cancers of the gastrointestinal tract by using non-invasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology. 2002 Sep;224(3):748-56.

  30. Kong SH, Park DO J, Lee HJ, Jung HC, Lee KU, Choe KJ, et al. Clinic pathologic features of asymptomatic gastric adenocarcinoma patients in Korea. Jpn J Clin Oncol. 2004 Jan;34(1):1-7.

  31. Adachi Y, Kitano S, Sugimachi K. Surgery for gastric cancer: 10-year experience worldwide. Gastric Cancer. 2001;4:166-74.

  32. Miki M. Usefulness of gastric cancer screening using the serum pepsinogen test method. Am J Gastroenterol. 2003;98:735-9.

  33. Onate-Ocana LF, Gallardo-Rincon D, Aiello-Crocifoglio V, Mondragon-Sanchez R, de-la-Garza-Salazar J. The role of pretherapeutic laparoscopy in the selection of treatment for patients with gastric carcinoma: a proposal for a laparoscopic staging system. Ann Surg Oncol. 2001;8(8):624-31.

  34. Ichikura T, Tomimatsu S, Uefuji K, Kimura M, Uchida T, Morita D. Evaluation of the New American Joint Committee on Cancer / International Union Against Cancer classification of lymph node metastasis from gastric carcinoma in comparison with the Japanese classification. Cancer. 1999;86:553-8.

  35. Suzuki T, Ochiai T, Hayashi H, Mori S, Shimada H, Isono K. Peritoneal lavage cytology findings as prognostic factor for gastric cancer. Sem Surg Oncol. 1999;17:103-7.

  36. Sánchez Socarrás V. Papel de la angiogénesis en el crecimiento tumoral. Rev Cubana Invest Biomed. 2001;20(3):223-30.

  37. Lacueva FJ, Calpena R, Medrano J, Teruel A, Mayol MJ, Graells ML, et al. Changes in P glycoprotein expression in gastric carcinoma with respect to distant gastric mucosa may be influenced by p53. Cancer. 2000;89:21-8.

  38. Metzger R, Leichman CG, Danenberg KD, Danenberg PV. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predictor response and survival for gastric cancer patients receiving combination cisplatin and fluoracil chemotherapy. J Clin Oncol. 1998;16:309.

  39. Mc Culloch P, Nita ME, Lazo H. Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev. 2004;(4):1526-31.

  40. Hartgrink HH, van de Velde CJ, Putter H. Extended lymph node dissection for gastric cancer. Who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol. 2004;22:2069-77.

  41. Csendes A, Burdiles P, Rojas J, Braghetto I, Diaz JC, Maluenda F. A prospective randomized study comparing D2 total gastrectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. Surgery. 2002 Apr;131(4):401-7.

  42. Maruyama K, Sasako M, Kinoshita T, Sano T, Katai H, Okajima K. Pancreaspreserving total gastrectomy for proximal gastric cancer. World J Surg. 1995 Jul- Aug;19(4):532-6.

  43. Roig J, Gironés J, Pujades M, Codina A, Quesada B. Cirugía laparoscópica en el cáncer gástrico. Cir Esp. 2004;76(6):376-81.

  44. Onate-Ocana LF, Gallardo-Rincon D, Aiello-Crocifoglio V, Mondragon-Sanchez R, de-la-Garza-Salazar J. The role of pretherapeutic laparoscopy in the selection of treatment for patients with gastric carcinoma: a proposal for a laparoscopic staging system. Ann Surg Oncol. 2001;8(8):624-31.

  45. Hartgrink HH, Putter H, Klein Kranenbarg E, Bonenkamp JJ, van de Velde CJ, Dutch Gastric Cancer Group. Value of palliative resection in gastric cancer. Br J Surg. 2002 Nov;89(11):1438-43.

  46. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006 Jun 20;24(18):2903-9.

  47. Suzuki T, Ochiai T, Hayashi H, Mori S, Shimada H, Isono K. Peritoneal lavage cytology findings as prognostic factor for gastric cancer. Sem Surg Oncol. 1999;17:103-7.

  48. Allum W, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc Am Soc Clin Oncol. 2003;22:249.

  49. González Moreno S, Sugarbaker PH. Comprehensive management of resectable gastric cancer: requirement for optimal clearance, containment and perioperative intraperitoneal chemotherapy. Rev Oncol. 2000;3:129-40.

  50. MacDonald JS, Smalley SR, Benedetti J. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725-30.

  51. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiation Oncology Biol Phys. 1998;8:1-4.

  52. Yoo CH, Noh SH, Shin DW, Choi SH, Min JS. Recurrence following curative resection for gastric carcinoma. Br J Surg. 2000;87:236-42.

  53. Kim KW, Choi BI, Han JK, Kim TK, Kim AY, Lee HJ, et al. Postoperative anatomic and pathologic findings at CT following gastrectomy. Radiographics. 2002;22:323-36.

  54. Marrelli D, Pinto E, De Stefano A, Farnetani M, Garosi L, Roviello F. Clinical utility of CEA, CA 19-9 and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001;181:16-9.

  55. De Potter T, Flamen P, Van Cutsem E, Penninckx F, Filez L, Bormans G, et al. Whole-body PET with FDG for the diagnosis of recurrent gastric cancer. Eur J Nucl Med. 2002;29:525-9.




2020     |     www.medigraphic.com